TH

Third Harmonic Bio IncNASDAQ THRD Stock Report

Last reporting period 30 Sep, 2023

Updated 22 Nov, 2024

Last price

Market cap $B

0.575

Micro

Exchange

XNAS - Nasdaq

THRD Stock Analysis

TH

Uncovered

Third Harmonic Bio Inc is uncovered by Eyestock quantitative analysis.

Market cap $B

0.575

Dividend yield

Shares outstanding

39.27 B

Third Harmonic Bio, Inc. develops pharmaceutical products for the treatment of allergic and immune diseases and disorders. The company is headquartered in San Francisco, California and currently employs 22 full-time employees. The company went IPO on 2022-09-15. The firm is focused on the development of medicine for the treatment of allergic and inflammatory diseases. Its lead product candidate, THB001, is a potent and highly selective, oral small molecule wild-type KIT inhibitor in development for the treatment of mast cell-mediated inflammatory diseases. KIT is a cell surface receptor that acts as the master survival and functional regulator of mast cells. Mast cells are a part of the immune system, and dysfunctional mast cell activity has been implicated in the pathophysiology of a range of allergic and other inflammatory disorders including urticaria, asthma and gastrointestinal disorders, among others. The company has completed Phase Ia clinical trial for THB001, which has demonstrated dose-dependent reductions of serum tryptase, a key biomarker of mast cell activity, which has been shown to correlate with clinical benefit in chronic urticaria patients.

View Section: Eyestock Rating